Results 1 to 25 of 25

Thread: Dnp Cycle

  1. #1
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94

    Dnp Cycle

    i will run a dnp cycle soon



    one capsule of 130 mg per day, during six weeks

    with one hour cardio every day

    like this, any side effects !


    and IT INCREase the metabolism at 10 % more..


    what do you think ????

    in this case, do i need supplements with this smaller dose ?

  2. #2
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    nobody ????

  3. #3
    Gear's Avatar
    Gear is offline HGH/IGF/Insulin Forum ~ AR-Hall of Famer
    Join Date
    Jul 2003
    Posts
    7,795
    I'll move this thread to the right section for you.

    And to answer your question, most people won't even cardio when on DNP , and doing DNP for 6 weeks is suicide. I would run DNP at about 250mg p/day for about 10 days. If you can't stand the sides, then lower the dose, if you feel ok then up the dose by a little. Do keep in mind that you may actually not feel any sides from DNP the first 3 - 4 days, if this is the case, do not increase the dose as DNP sides usually suddnley appear out of no where.

    -Gear

  4. #4
    goose is offline Banned
    Join Date
    Aug 2005
    Location
    England...
    Posts
    2,832
    130 mg is a waste.Please do your research with this drug,it`s clear you have not done any,as you can fry your organs inside your body and die.

  5. #5
    goose is offline Banned
    Join Date
    Aug 2005
    Location
    England...
    Posts
    2,832
    Woops.I did not read 6 weeks.I`m not quite sure on this.As I have never done that type of thing.

  6. #6
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    Couldn't a light dose be used with supplementing T3 for an extended time period and in this way maintaining a rise in metabolism without too much risk??
    Just wondering

    SHAGGY

  7. #7
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    i read the article of sv1, and he said that like this, it increase the metabolism and not risk

    so i dont think that it s not safe

    and it s not suicide,because my dose is safe,130 mg increase the temp body to 10 %...

    please read this before to critiq my pct : DNP (2,4-Dinitrophenol) Info

  8. #8
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    goose, the girl with red hair is pretty...

  9. #9
    fred9's Avatar
    fred9 is offline Member
    Join Date
    Sep 2004
    Location
    Holland
    Posts
    598
    ive done a 7 week dnp cycle in the past..not something to recommend..after a few weeks even 200mg makes u incredible hot, the dnp is then quite well buildup into your system..

    i definately gonna do from now on 2 weeks cycles...i really lost an incredible amount of strength during that long cycle..and the sweats didnt go away after stopping the dnp...1-2 months later the sweating dissapeared..

    2 weeks cycle with 400-500mg dnp + igf is the way to go..btw slin or igf is almost needed while you on dnp, goose or another member explained it in detail why it's needed...
    one thing i remember is that cataracts can develope when blood sugar is high..this happens when u are on dnp and igf/slin prefents this.. so the igf and slin combats the side effects..

  10. #10
    goose is offline Banned
    Join Date
    Aug 2005
    Location
    England...
    Posts
    2,832
    Quote Originally Posted by fred9
    ive done a 7 week dnp cycle in the past..not something to recommend..after a few weeks even 200mg makes u incredible hot, the dnp is then quite well buildup into your system..

    i definately gonna do from now on 2 weeks cycles...i really lost an incredible amount of strength during that long cycle..and the sweats didnt go away after stopping the dnp...1-2 months later the sweating dissapeared..

    2 weeks cycle with 400-500mg dnp + igf is the way to go..btw slin or igf is almost needed while you on dnp, goose or another member explained it in detail why it's needed...
    one thing i remember is that cataracts can develope when blood sugar is high..this happens when u are on dnp and igf/slin prefents this.. so the igf and slin combats the side effects..

    I read your great thread on your long term use with DNP,Very interesting.Agreed on the slin and IGF,infact as you know fred you cant really go hypo when on DNP with slin or IGF,so this is the perfect chance to run slin and IGF together with no risk.You have to take advatage of this,as you are diabetic with DNP.As you said Crystal DNP at 500 is just perfect,EASY....

  11. #11
    goose is offline Banned
    Join Date
    Aug 2005
    Location
    England...
    Posts
    2,832
    Quote Originally Posted by the.tunisian.muscle
    nobody ????

    United States Patent
    4,673,691


    Bachynsky June 16, 1987
    Human weight loss inducing method
    Abstract
    A human weight reduction method in which 2,4-dinitrophenol and a thyroid hormone preparation are administered to the
    patient. The dinitrophenol is administered in dosages sufficient to elevate the patient's body temperature, typically 250 mg
    every other day. The thyroid hormone preparation preferably contains 3,5,3'-triiodothyronine and is administered in dosages
    sufficient to substantially maintain the patient's serum T3 concentration originally present at treatment onset.
    Inventors:
    Bachynsky; Nicholas (1110 Pine Cir., Sea Brook, TX 77586)
    Assignee: Bachynsky; Nicholas (Sea Brook, TX)
    Appl. No.: 668501


    Filed:
    November 5, 1984
    Current U.S. Class: 514/567; 514/909


    Intern'l Class:
    A61K 031/195


    Field of Search:
    514/728,909,567


    References Cited
    [Referenced By]


    U.S. Patent Documents
    4087554
    May., 1978 Haydock et al. 514/728.


    Other References
    Chem. Abst. 66:82758c (1967)--Rossini et al.
    Chem. Abst. 71:27671x (1969)--Tomita et al.
    Chem. Abst. 77:109780v (1972)--Tiller et al.
    Chem. Abst. 82:25791q (1975)--Wahl et al.
    Chem. Abst. 88:167300b (1978)--Kaplan et al.
    Chem. Abst. 89:191455x (1978)--Organesyan et al.
    Chem. Abst. 100:168805y (1984)--Sydykov.
    Chem. Abst. 102:56608w (1985)--Langer.
    Simkins, S., "Dinitrophenol and Desiccated Thyroid in the Treatment of Obesity," JAMA 108, pp. 2110-2117
    and 2193-2199 (1937).
    Tainter, M. L. et al., "Dinitrophenol in the Treatment of Obesity," JAMA 105, pp. 332-336 (1935).
    Tiller, F. W. et al., "The Effects of Noradrenaline and 2,4-Dinitrophenol on the Oxygen Consumption of
    Different-Aged Rats After Treatment with Triiodothyronine or Methylthiouracil," Arch. Int. Pharmacodyn. 198,
    pp. 377-384 (1972) (With Translation).
    Wahl, R. et al., "Influence of Various Drugs on the Adsorption of Thyroid Hormones to Liver Mitochondria," Z.
    Naturforsch, 29, pp. 608-617 (1974) (With Translation).
    Schimmel, M. et al., "Thyroidal and Peripheral Production of Thyroid Hormones," Annals of Internal Medicine
    87, pp. 760-768 (1977).
    Arena, Jay M., Poisoning, pp. 86 and 92 (Charles C. Thomas, Springfield, Ill. (1978).
    Cazeneuve, P. et al., "Sur les effets produits par l'ingestion et l'infusion intra-veineuse de trois colorants jaunes,
    derives de la houille," C.R. Acad. Sci. 101, pp. 1167-1169 (1885).
    Brobeck, J. R., "Food Intake as a Mechanism of Temperature Regulation," Yale Journal of Biology and
    Medicine 20, pp. 545-552 (1948).
    Cutting, W. C. et al., "Actions and Uses of Dinitrophenol," JAMA 101, pp. 193-195 (1933).
    Diechmann, W. B. et al., Symptomatology and Therapy of Toxicological Emergencies, pp. 452-453 (Academic
    Press, New York 1964).
    Counsel on Pharmacy and Chemistry, "Dinitrophenol Not Acceptable for N.N.R.," JAMA 105, pp. 31-33 (1935).
    Horner, W. D., "Cataract Following Dinitrophenol Treatment for Obesity," Archives of Opthalmology 16, pp.
    447-461 (1936).
    Negherbon, W. O., Handbook of Toxicology, vol. 3, pp. 303-308, (W. B. Saunders Co., Philadelphia 1959).
    Perkins, R. G. "A Study of the Munitions Intoxications in France," Public Health Reports 34, pp. 2335-2374
    (1919).
    Sims, E. A. H. et al., "Endocrine and Metabolic Effects of Experimental Obesity in Man," Recent Progress in
    Hormone Research 29, pp. 457-496 (1973).
    Spector, W. S., Handbook of Toxicology, vol. 1, p. 118, (W. B. Saunders Co., Philadelphia, 1956).
    Tainter, M. L. et al., "A Case of Fatal Dinitrophenol Poisoning," JAMA 102, pp. 1147-1149 (1934).
    Physician's Desk Reference, 37th ed., pp. 1896-1897 (1983).
    Primary Examiner:
    Robinson; Douglas W.


    Attorney, Agent or Firm:
    Pravel, Gambrell, Hewitt & Kimball


    Claims
    I claim:
    1. A method of inducing weight loss in a patient, comprising the steps of:
    (a) administering 2,4-dinitrophenol or salt thereof at a rate ranging from about 60 to about 250 mg/day; and
    (b) concurrently administering 3,5,3'-triiodothyronine to the patient at a rate ranging from about 25 to about 100 mcg/day.
    2. The method of claim 1, wherein said 3,5,3'-triiodothyronine is substantially free of thyroxine.
    3. The method of claim 1, wherein said 3,5,3'-triiodothyronine administration is at a rate ranging from about 50 to about 100
    mcg/day.
    4. The method of claim 1, wherein said dinitrophenol is administered at said rate with dosages given only on alternate days.
    5. The method of claim 1, wherein said dinitrophenol is administered at said rate with primary dosages given on alternate days
    and smaller, supplemental dosages given on the days immediately subequent to said alternate days.
    6. The method of claim 1, wherein 2,4-dinitrophenol is administered.
    7. A method of inducing weight loss in a patient, comprising the steps of:
    (a) administering 2,4-dinitrophenol to the patient at a rate ranging from about 125 to about 250 mg/day; and
    (b) concurrently administering 3,5,3'-triiodothyronine substantially free of thyroxine to the patient at a rate ranging from about
    50 to about 100 mcg/day.
    8. The method of claim 7, wherein said dinitrophenol and said 3,5,3'-triiodothyronine are administered at initial rates of about
    250 mg of said dinitrophenol every other day and about 50 mcg 3,5,3'-triiodothyronine per day, and following 2-12 weeks of
    said administration at said initial rates, are administered at subsequent rates of about 250 mg of said dinitrophenol every other
    day alternated with about 125 mg of said dinitrophenol on subsequent days and about 100 mcg 3,5,3'-triiodothyronine per day.
    Description
    This invention relates to a method of inducing weight loss in patients by the concurrent administration of 2,4-dinitrophenol and
    3,5,3'-triiodothyronine.
    BACKGROUND OF THE INVENTION
    Obesity is a common problem. Simply stated, obesity is an excess accumulation of adipose tissue which contains fat stored in
    the form of triglycerides. The number of cells in the body is determined at least by late adolescence and while the number of
    adipocyte cells may increase, it does not decrease. Thus, weight gain can result from an enlargement of adipocyte cells or an
    increase in their number. Typically, obese individuals have hypertrophic cells and the severely obese have an increase in
    adipose cell number as well as hypertrophy. An obese patient only reduces the fat in his cells when he loses weight. Further, he
    may not ever lose the tendency to gain weight.
    Body weight is regulated by an endogenous body mechanism. Physiological and neurological properties establish and maintain
    a given weight. Briefly stated, glycerol which is released during hydrolysis of triglycerides and adipose tissue is widely
    believed to regulate caloric intake and metabolism. Others have postulated that caloric intake is affected by both body
    temperature and environmental temperature. In addition, cell size and number affect energy regulation. Weight gain cannot be
    predicted solely on the amount of calories ingested.
    In normal persons, thermogenesis is an adaptive mechanism which increases the metabolic rate after overeating. While a
    normal person will experience an increase in thermogenesis following increased caloric intake, the obese either has a
    substantially decreased thermogenic mechanism or lacks this particular mechanism entirely.
    The use of dinitrophenol to treat obesity is known. Dinitrophenol is known to elevate the body temperature and produces a
    marked increase in caloric metabolism. However, ingestion of massive amounts of dinitrophenol causes toxicity by the
    uncoupling of oxidative phosphorylation in the mitochondria of cells. Because of this toxicity, excessive amounts can result in
    profuse diaphoresis, fever, thirst, tachycardia and respiratory distress which can lead to hyperpyrexia, profound weight loss,
    respiratory failure and death. The minimum fatal human oral dose is estimated at one to three grams (approximately 20-30
    mg/kg).
    In methods heretofore known to using dinitrophenol to induce weight loss, while initial daily dosages have usually been much
    less than the toxic amount, about 100-250 mg, as the treatment progressed the patient normally developed a tolerance for
    dinitrophenol and the dosage was increased to obtain the same results. This increased dosage led to an increased frequency of
    toxic symptoms and general disuse of dinitrophenol in inducing weight loss.
    It has also been known to use drugs with thyroid hormone activity for the treatment of obesity. However, as described in
    Physicians' Desk Reference, Medical Economics Co. Inc., (Oradell, N.J.), 37th Ed. (1983), in euthyroid patients, it is well
    established that doses within the daily hormonal requirements are ineffective for weight reduction. However, larger doses may
    produce serious or even life-threatening manifestations of toxicity.
    SUMMARY OF THE INVENTION
    The present invention avoids the necessity of increased dosages of dinitrophenol and the concomitant toxicity problems
    associated therewith as treatment progresses while obtaining improved results. It has been discovered that the use of
    dinitrophenol induces hypothyroidism which can be prevented by concurrently administering thyroid hormone preparation
    with the dinitrophenol.
    Briefly, the present invention is a method of inducing weight loss in patients, including the steps of administering
    dinitrophenol to the patient in an amount sufficient to clinically increase thermogenesis of the patient, and concurrently
    administering a thyroid hormone preparation to the patient in an amount sufficient to substantially maintain the serum
    concentration of 3,5,3'-triiodothyronine of the patient originally present at treatment onset.
    DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
    It has been discovered that the ingestion of dinitrophenol induces hypothyroidism. Athough it is not fully understood, it is
    believed that the normal thyroid gland produces both thyroxine (referred to herein as T4) and 3,5,3'-triiodothyronine (referred
    to herein as T3). However, approximately eighty percent of the serum T3 present in the body is produced by the extrathyroidal
    monodeiodination of T4 to T3. When dosages of dinitrophenol are taken, hypothyroidism is induced, not by a reduction in
    activity of the thyroid, but by a reduction of the rate of extrathyroidal conversion of T4 to T3. While both T4 and T3 are
    biologically active, T3 is much more active than T4. Thus, the reduction in serum T3 concentration induced by taking
    dinitrophenol substantially offsets the metabolic effect of the dinitrophenol. By analogy, the reduction in serum T3
    concentration is similar to that observed in fasting patients. Typically, normal serum T3 concentration ranges from about 70 to
    about 200 ng/dl.
    It has further been discovered that deficient serum T3 concentrations resulting from administration of dinitrophenol can be
    restored to normal concentrations by concurrently administering a thyroid hormone preparation therewith.
    In practicing the method of this invention, dinitrophenol is administered to the patient. The metabolically active dinitrophenols
    suitable for use in the invention include 2,4-dinitrophenol and the salts thereof. By the term administration is meant any
    suitable manner of introducing the medication into the patient's body, including orally (p.o.) and topically. The preferred
    manner of administering dinitrophenol is orally, as in the form of a tablet or capsule.
    The amount of dinitrophenol given should be sufficient so that the patient experiences increased body temperature. Preferably,
    the body temperature is elevated approximately 1.degree. F. The dose of dinitrophenol required to obtain this result varies from
    patient to patient, depending on factors such as, for example, weight, age, health, environmental conditions, physical activity,
    nutrition, and psychological state, but will normally be in the range of from about 60 to about 500 mg per day, or about 0.60 to
    about 5.0 mg/kg of body weight per day. Preferably, the dinitrophenol is administered in daily or alternating daily dosages,
    insuring that no cumulative effective results, such as excessive thermogenesis.
    It is essential that the amount of dinitrophenol administered not exceed toxic doses. In a few patients, adverse reactions may
    occur at dosages of dinitrophenol which are not effective to elevate the body temperature, contraindications including any
    clinical state in which there is hypermetabolism, such as hyperthyroidism, ongoing infections, and pregnancy, and any other
    clinical conditions such as heart disease, chronic obstructive pulmonary disease, Addison's disease, liver disorders, or renal
    failure. Most are safely treated with suitable results from the aforementioned dosages.
    Concurrently with the administering of the dinitrophenol, or shortly thereafter, a thyroid hormone preparation is administered
    to the patient. As used herein, the term thyroid hormone preparation includes any suitable preparation which restores the serum
    T3 concentration, including preparations containing 3,5,3'-triiodothyronine, thyroxine, derivatives thereof or combinations
    thereof. Preferably, the thyroid hormone preparation contains T3. Because of the varying potency of such preparations,
    dosages of thyroid harmone preparation are reported herein on a T3 equivalent basis.
    The thyroid hormone preparation is administered in an amount sufficient to maintain the pretreatment serum T3 concentration
    in the patient, typically about 70-200 ng/dl in normal patients. Generally, from about 25 to about 200 mcg T3 equivalent per
    day, or from about 0.3 to about 2.7 mcg T3 equivalent per kilogram of body weight per day, is sufficient. Preferably, the
    thyroid hormone preparation is administered daily. In an especially preferred embodiment, the thyroid hormone preparation is
    administered orally with the dinitrophenol.
    As described above, the rate of extrathyroidal conversion of T4 to T3 may vary as treatment with the dinitrophenol progresses.
    Thus, it may be necessary to increse or decrease the dosage of the thyroid hormone preparation accordingly.
    It is preferred that in the practice of the method of this invention, the patient be closely monitored, especially in the initial
    stages of treatment. Recommended pretreatment and initial treatment protocol includes physical examination,
    electrocardiogram, and stress electrocardiogram if indicated, complete blood count, urinalysis, thyroid function studies (T3, T4
    and reverse T3), serum electrolytes, HDL cholesterol, serum creatinine, blood urea nitrogen, uric acid, calcium, pulmonary
    function tests and liver function tests including liver enzymes, biliribin, and alkaline phosphatase.
    In an especially preferred embodiment, the patient is started on initially lower dosage rates of dinitrophenol, about 250 mg
    every other day, and thyroid hormone preparation, about 25-50 mcg/day on a T3 equivalent basis. After 2-12 weeks of this
    treatment, if no adverse reactions are noted, the dosage rates may be increased to about 250 mg dinitrophenol alternated daily
    with about 125 mg, i.e. 250 mg on even-numbered days and 125 mg on odd-numbered days, and to about 100 mcg/day thyroid
    hormone preparation on a T3 equivalent basis. When the weight goal of the patient is achieved, the administration of the
    dinitrophenol may be discontinued, and the thyroid hormone preparation continued to maintain the patient's weight. While
    dietary control need not be strict, weight loss and weight maintenance are facilitated by moderate caloric intake of less than
    about 1800 calories per day, during and following treatment.
    This method is illustrated by way of the case histories which follow.
    Case 1
    A white female 31 years of age with a weight in excess of 200 pounds had attempted to loss weight with various diet plans.
    She had only been able to achieve about a 20-pound loss, and had immediately regained the weight. The patient was
    nulliparous and had no ongoing medical problems. Upon physical examination, she had a weight of 208.5 pounds, a height of 5
    feet, 3 inches, and a blood pressure of 132/80, without any goiter. Laboratory analyses, including complete blood count, liver
    profile, serum electrolytes, kidney function tests and thyroid function tests, were all within normal limits. Because of her
    familial history of heart disease, she underwent a stress electrocardiogram which was normal other than early fatigue and calf
    cramping.
    The patient was started on CYTOMEL brand of liothyronine sodium (manufactured by Smith, Kline and French), 50 mcg/day
    p.o., and on 2,4-dinitrophenol, 250 mg every other day p.o. On the 19th day of medication, the patient had normal vital signs
    and the dosages were increased to 100 mcg/day liothyronine, and 250 mg/day dinitrophenol alternated every other day with
    125 mg/day. The patient was subsequently maintained on these dosages and returned for follow-up examinations
    approximately every 3 weeks. The weight loss history is seen in Table 1. After 241 days of medication, the patient has
    achieved her weight goal of 135 pounds. Administration of the dinitrophenol was discontinued and the patient was maintained
    on liothyronine, 100 mcg/day p.o. No weight gain was subsequently observed.
    TABLE 1
    ______________________________________
    Day Weight (lbs)
    ______________________________________
    1 208 1/2
    19 202 1/2
    35 196 1/2
    49 189 1/2
    69 184
    92 175
    113 167
    134 160
    155 152 1/2
    180 148
    206 146
    241 135
    ______________________________________
    Case 2
    A male 40 years of age with a weight of approximately 250 pounds had attempted to lose weight with a variety of diet plans
    and diet medications. Success had been limited to 5-10 pound weight losses, with immediate regain. On physical examination,
    the patient has a height of 5 feet, 10 inches, a weight of 255 pounds and a blood pressure of 160/100. Complete blood count,
    SMAC, serum electrolytes, thyroid function tests, glucose tolerance tests and stress electrocardiogram were normal.
    The patient was started on liothyronine, 50 mcg/day p.o., and on dinitrophenol, 250 mg every other day p.o. After two weeks,
    the blood pressure returned to normal (130/80), and the dosages were increased to 100 mcg/day liothyronine and 250 mg
    dinitrophenol alternated daily with 125 mg. The weight loss history is presented in Table 2. Once the weight goal of 167
    pounds had been achieved, the patient was taken off the dinitrophenol administration and the 100 mcg/day liothyronine
    medication was maintained. The patient was instructed to restrict caloric intake to approximately 1800 calories per day. No
    subsequent weight gain was observed.
    TABLE 2
    ______________________________________
    Day Weight (lbs)
    ______________________________________
    1 255
    14 241
    30 232
    44 227
    65 220
    76 214
    97 208
    125 203
    153 197 3/4
    181 193
    209 189
    279 178
    321 167
    ______________________________________
    Case 3
    A white male 38 years of age with a weight of approximately 342 pounds had made numerous attempts to lose weight "with all
    methods" without any success. Upon physical examination, the patient had a weight of 352 pounds, a height of 5 feet, 11
    inches and a blood pressure of 150/110. Other than a slight enlargement of the heart on X-ray and +3 pitting edema, the
    physical examination was unremarkable. Laboratory analysis initially revealed a blood sugar of 372 with a glycohemoglobin
    of 14.3 (normal 4.4-8.2). The remaining tests, including stress electrocardiogram, were within normal limits. The patient was
    started on liothyronine, 50 mcg/day p.o., and dinitrophenol, 250 mg every other day, and was instructed to restrict his caloric
    intake to approximately 1800 calories per day. On the 59th day of treatment, the dosages were increased to 100 mcg/day
    liothyronine, and 250 mg/day dinitrophenol alternated every day with 125 mg. The patient's weight loss history is presented in
    Table 3. Following treatment, the dinitrophenol administration was discontinued and the patient was maintained on
    liothyronine, 100 mcg/day p.o. and instructed to maintain his caloric intake to approximately 1800 calories per day. No
    subsequent weight gain was observed.
    TABLE 3
    ______________________________________
    Day Weight (lbs)
    ______________________________________
    1 354
    24 333
    38 314
    59 317
    80 297 1/4
    101 288
    122 275
    143 260 1/2
    164 254
    185 243 1/2
    206 246
    227 235 1/2
    248 234
    269 229
    290 222
    ______________________________________
    The above cases illustrate the effectiveness of the method with obese patients unable to reduced their weight by conventional
    methods.
    Having described any weight loss method above, many variations in the details thereof will occur to those skilled in the art. It
    is intended that all such variations which fall within the scope and spirit of the appended claims be embraced thereby.
    * * * * *

    I think this is could help you.Remember this study is for very VERY fat people.

  12. #12
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    yes i read it, but read this

    4. This is for all you office guys....I know exactly how you feel.

    200mg/day will make most people sweat in a suit if they
    move around a lot, however 100mg/day WILL NOT.

    I have personally tried this dosage and I didn't even FEEL
    IT.

    At 100mg/day, dehydration isn't really an issue.
    Steroids CAN ACTUALLY be taken at this dosage,
    and muscle gain is POSSIBLE.
    Your metabolism is amped up by 10%

    Compared to 3% to ECA, 4% to Clen , and 7-8% from
    Beta-agonists+T3

    And to boot, DNP DOES NOT give you ANY of the side
    effects associated with high-doses of stimulants
    because IT DOES NOT WORK THROUGH the
    cardiovascular system.


    i think that s clear, dnp AT low dose can help you to increase metabolism
    Last edited by the.tunisian.muscle; 02-18-2007 at 07:07 AM.

  13. #13
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    Yes, even at a low dose the DNP will influence your metabolism, what I have been thinking about is that maybe when doing a low dose of DNP for an extended timeframe you should supplement with a low dose of T3, the reason being that after a while the DNP would inhibit your endogenous(sp??) T4 being converted to T3, but I don't know how pronounced this effect would be at a low dose.
    If this effect would be very strong at a low dose wouldn't it mean that by taking the DNP at a low dose and not supplementing with T3 the rise in metabolism would be small because even if the DNP rises metabolism(keep in mind it is dosed low), a substantial amount of your metabolism would be lowered again by the dropping of ones own T3 levels??
    Don't know though, just wondering.

    Have you started your DNP cycle yet tunisian??

    SHAGGY

    edit; spelling
    Last edited by SHAGGY; 02-18-2007 at 12:30 PM.

  14. #14
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    not yet,i wait my dnp , it comes in 4 days !


    shaggy, speak with me french forasmuch as you are from belgium.


    thanks.

  15. #15
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    Quote Originally Posted by fred9
    ive done a 7 week dnp cycle in the past..not something to recommend..after a few weeks even 200mg makes u incredible hot, the dnp is then quite well buildup into your system..

    i definately gonna do from now on 2 weeks cycles...i really lost an incredible amount of strength during that long cycle..and the sweats didnt go away after stopping the dnp...1-2 months later the sweating dissapeared..

    2 weeks cycle with 400-500mg dnp + igf is the way to go..btw slin or igf is almost needed while you on dnp, goose or another member explained it in detail why it's needed...
    one thing i remember is that cataracts can develope when blood sugar is high..this happens when u are on dnp and igf/slin prefents this.. so the igf and slin combats the side effects..

    ANd how much fat did you lose it ????

    WHAT mean "to go btw" ????

  16. #16
    fred9's Avatar
    fred9 is offline Member
    Join Date
    Sep 2004
    Location
    Holland
    Posts
    598
    Quote Originally Posted by the.tunisian.muscle
    ANd how much fat did you lose it ????

    WHAT mean "to go btw" ????
    btw=by the way..

    don;t know exactly how much fat i lost i think i started @ 10-12%bf..at the end of the ride i was on approx5%..

    nice posts goose!!

  17. #17
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    I will try tunisian, but my french is pretty bad, and if we speak french it is offcourse better limited to PM's, otherwise most board members would not understand what we are saying. Do you speak any dutch??
    Keep us updated on the DNP , is it crystal or powder version??

    SHAGGY

  18. #18
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    spreek je nederlands ????


    dnp , i dunno if it s crystal or powder but i guess that s powder because caps are yellow
    (i know the color because my friend has order from him)

    so if fred lost a lot of fat with his cycle, it means that my idea (dnp 130 mg on 6 weeks) is not bad Because my cycle look like his cycle


    but now, i think that i will couple it with t3, and igf and slin

    i guess that it s the good combo

    no ?????
    Last edited by the.tunisian.muscle; 02-18-2007 at 10:08 AM.

  19. #19
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    "Spreek je nederlands??"

    Translation; "Do you speak dutch?"

    Ja geen probleem, als je verder wil spreken stuur me dan een PM, zo storen we de rest niet met ons nederlands.


    Translation; " Yes, no problem, if you wish to speak in dutch more, send me a PM, this way we won't bother the others with our Dutch."

    SHAGGY

  20. #20
    cj1capp's Avatar
    cj1capp is offline Anabolic Member
    Join Date
    Oct 2003
    Posts
    2,267
    i use dnP but i just wanted you to be aware of Bachynsky and his thoughts on dnp uses in obesity treatment and cancer treatment.
    check out this http://www.quackwatch.org/01Quackery...ncer/icht.html

    http://www.casewatch.org/doj/shantha/indictment.shtml

  21. #21
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    That is supposedly a good combo, but if you don't have any experience with all of those before and on their own, I really wouldn't combine them. Use the DNP on its own for two weeks at a light dose to see how you react to it and to get familiar with how it makes you feel, then take a break for a few weeks, if you still want to lose weight you can try it again and if you really want, incorporate one of the other aids in at a time. Seems to be a much safer way of doing it than to jump on everything the first time you use DNP, it is a harsh substance on its own, in combination it is more difficult to handle it would seem to me.

    SHAGGY

  22. #22
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    ok i will do it


    but nederlands is netherlands and not deutsch...no ?

  23. #23
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    In English;
    Dutch= Nederlands(the language spoken in Belgium and The Netherlands/Holland)
    German= Duits(the language spoken in Germany).

    By the way; you have PM, feel free to ask me any questions in Dutch(Nederlands) via PM.

    SHAGGY

  24. #24
    Join Date
    Feb 2007
    Location
    brussels, belgium
    Posts
    94
    Quote Originally Posted by SHAGGY
    In English;
    Dutch= Nederlands(the language spoken in Belgium and The Netherlands/Holland)
    German= Duits(the language spoken in Germany).

    By the way; you have PM, feel free to ask me any questions in Dutch(Nederlands) via PM.

    SHAGGY


    dank u (thanks)

  25. #25
    SHAGGY is offline Member
    Join Date
    Feb 2003
    Location
    Belgium
    Posts
    531
    Geen probleem, graag gedaan. (No problem, it was my pleasure.)


    SHAGGY

Thread Information

Users Browsing this Thread

There are currently 1 users browsing this thread. (0 members and 1 guests)

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •